Verrica Pharmaceuticals Inc. (VRCA)

In November 2025, Verrica completed a $50 million private placement financing and reported its Q3 2025 financial results. In December 2025, the first patient was dosed in its global Phase 3 program evaluating YCANTH for common warts. In February 2026, Verrica announced the launch of YCANTH in Japan by its partner Torii Pharmaceutical. In March 2026, Verrica reported its Q4 and full-year 2025 financial results. In April 2026, Verrica announced the acceptance of a late-breaking abstract highlighting the potential abscopal effect of VP-315 for basal cell carcinoma.

Demand for Verrica Pharmaceuticals' product YCANTH has shown some seasonality. The company anticipated some slowdown in Q4 due to holidays but expected momentum to pick up in the following year, particularly during the cold and flu season. Despite these seasonal fluctuations, Verrica has reported strong demand-led growth for YCANTH.

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company focused on developing and commercializing medications for skin diseases requiring medical intervention. Their primary commercial product is YCANTH®, approved in the United States for the treatment of molluscum contagiosum. The company is also developing YCANTH for potential follow-on indications and VP-315 for dermatologic oncologic conditions.

Verrica Pharmaceuticals Inc. is headquartered in West Chester, Pennsylvania, United States. Its commercial operations for YCANTH are primarily in the United States, but YCANTH has launched in Japan through a partnership with Torii Pharmaceutical Co., Ltd. Verrica is also initiating activities to support a future regulatory submission for YCANTH in the European Union.

In the past year, Verrica Pharmaceuticals' reputation has been affected by legal investigations. Investigations relate to allegations that the company intentionally misled investors about the prospects of obtaining FDA approval for YCANTH by concealing known quality control problems at its contract manufacturer.

Verrica Pharmaceuticals Inc. has a mix of institutional and individual owners. As of April 4, 2026, there were 52 institutional owners holding a total of 5,196,157 shares. Paul B. Manning is a significant individual shareholder, owning 60.05% of the company's shares. Insiders collectively own a significant proportion of the company, with individual insiders holding 38% ownership as of May 2024.